Develops drugs for glioblastoma and rare diseases.
Dec 2025Revenue $1.18M/yrExpenses $11.5M/yr
No trendCash runway ≈ 5 months from Dec 2025
Figures by year
When will BioLineRx be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $1.18M and expenses $11.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.18M | $11.5M | −$10.3M |
| Dec 2024 | $28.9M | $49.3M | −$20.4M |
| Dec 2023 | $4.80M | $54.5M | −$49.7M |
| Dec 2022 | $0.00 | $29.2M | −$29.2M |
| Dec 2021 | $0.00 | $24.8M | −$24.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.